Chemomab Reports $6.7M Cash, Sets Nebokitug Phase 2 Timeline
CMMB sits 54% above its 52-week low of $1.35 on light trading volume (0.1× avg).
Summary
Chemomab disclosed Q2 2026 results with $6.7M in cash and equivalents as of June 30, 2026, and a net loss of $2.17M, or $0.003 per share. The company expects its Nebokitug RA Phase 2 trial to begin in H1 2027 with data readout in H1 2028. Chemomab believes existing liquidity resources as of June 30 will fund operations through Q1 2027. The merger with Scipher Medicine, announced July 8, is expected to close before the end of 2026, and HBM Healthcare disclosed a 12.5% stake. The cash position is modest relative to the planned trial timeline, and the merger remains the dominant near-term catalyst.
At the time of this announcement, CMMB was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $1.35 to $4.12. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.